Future Perspective of the Application of Positron Emission Tomography-Computed Tomography-MR Imaging in Musculoskeletal Disorders

Angelini, Andrea; Castellucci, Paolo; Ceci, Francesco

doi:10.1016/j.cpet.2018.08.012

Cited by 6 publications

(1 citation statement)

References 79 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of FDG-PET/CT in predicting response in sarcoma is currently not clear. 14 – 16 Table 3 illustrates the significant correlation between anatomic and metabolic responses in the evaluable patients. Our data showed no significant difference in anatomic responses based on mean SUV at baseline, but did show a significant difference at cycle 3; where those with PR + SD had a lower mean SUV at this time point as compared to those with PD.…”

Section: Discussionmentioning

confidence: 99%

Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma

et al. 2021

View full text Add to dashboard Cite

Historically, administration of dacarbazine to sarcoma patients was limited by frequent treat-ment-related nausea/vomiting and neutropenia. These toxicities are now largely preventable with contemporary antiemetics and growth factor support. In this single-arm, phase II study, dacarbazine 850 mg/m2 was given on day 1 of each 3-week cycle until disease progression or intolerance with prophylactic serotonin-3 receptor, neurokinin-1 antagonists, corticosteroids, and pegfilgrastim. Coprimary endpoints included clinical benefit rate (CBR), and any grade of nausea/vomiting and/or grade 3–4 neutropenia. With a sample size of 80 patients, >24 patients with clinical benefit would indicate that the CBR exceeds the historical (<20%) [Power 0.80; alpha 0.05]. In addition, we hypothesized that the rates of nausea/vomiting would be 27% and grade 3–4 neutropenia would be 1% (historical: 90% and 36%, respectively) [power 0.95; alpha 0.05]. The CBR was 30% (24 patients: PR-2 and stable-22). The rate of nausea/vomiting was 37.5% (31 patients) and grades 3–4 neutropenia was 10% (8 patients). Median time-to-progression was 8.1 weeks (95% CI 8–9.7) and median overall survival was 35.8 weeks (95% CI 26.2–55.4). PET scans demonstrated no association with response. Modern prophylactic anti-emetics and pegfilgrastim given with dacarbazine reduced the rates of treatment related nausea/vomiting and serious neutropenia.

show abstract

Section: Discussionmentioning

confidence: 99%